Torrent Pharmaceuticals (TORNTPHARM) Fundamentals 2026 — P/E 78.8x, Revenue Analysis | SniperIQ
Torrent Pharmaceuticals (TORNTPHARM) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹1.70 Lakh Crore, trading at ₹5035.40 on the BSE. This SniperIQ fundamentals page covers Torrent Pharmaceuticals's valuation (P/E 78.8x, P/B 20.3x), profitability (net margin 15.6%), revenue (₹13,980 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Torrent Pharmaceuticals's market cap?
Torrent Pharmaceuticals (TORNTPHARM) has a market capitalization of approximately ₹1.70 Lakh Crore, trading at ₹5035.40 on the BSE. Market cap moves with the live share price.
What is Torrent Pharmaceuticals's P/E ratio?
Torrent Pharmaceuticals's trailing twelve-month P/E ratio is 78.8x, with a price-to-book (P/B) of 20.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Torrent Pharmaceuticals?
Torrent Pharmaceuticals runs a net profit margin of 15.6%, a gross margin of 66.1%, and an operating margin of 24.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Torrent Pharmaceuticals generate?
Torrent Pharmaceuticals reported revenue of ₹13,980 Crore for fiscal year 2026, with net income of ₹2,163 Crore and earnings per share (EPS) of 63.92. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Torrent Pharmaceuticals pay a dividend?
Torrent Pharmaceuticals offers a trailing dividend yield of about 0.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Torrent Pharmaceuticals financially healthy?
Torrent Pharmaceuticals carries a debt-to-equity ratio of 1.79x and a current ratio of 1.13x, with a market beta of 0.13. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Torrent Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Torrent Pharmaceuticals (TORNTPHARM) the key facts are: market cap ₹1.70 Lakh Crore, P/E 78.8x, revenue ₹13,980 Crore, 52-week range 2891.45-5056.4. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Torrent Pharmaceuticals's full fundamentals live
Get Torrent Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.